All News

Corey Cutler, MD, MPH, FRCPC, discusses how patients with blood cancer in need of an umbilical cord blood transplant may benefit from omidubicel-onlv.

The FDA expresses openness towards having protocol discussions with investigators on initiating a second clinical study evaluating synthetic hypericin sodium for cutaneous T-cell lymphoma.

An expert from University Hospitals highlights different guidelines penned by oncology organizations informing the integrative management of symptoms including anxiety and depression in patients with kidney cancer.

Patients with hematologic malignancies who require allogenic hematopoietic stem cell transplant can now receive omidubicel following the FDA’s approval of the agent.

Data from the phase 3 KarMMA-3 trial support several applications for idecabtagene vicleucel in earlier use for triple-class exposed multiple myeloma in the United States, Europe, and Japan.

Fareed Khawaja, MBBS, and Marilyne Daher, MD discuss COVID-19 vaccine efficacy and safety among patients with cancer in the United States.

An expert from Dana-Farber Cancer Institute highlights the unmet needs that sacituzumab govitecan meets in the treatment of advanced hormone receptor-positive, HER2-negative breast cancer.

Massage and acupuncture represent promising integrative care strategies for managing stress and pain in patients with kidney cancer and other tumors, according to an expert from University Hospitals.

A senior physician’s assistant from Johns Hopkins examines why adverse effect management is so crucial and reviews how to help maintain quality of life while undergoing treatment.

Findings from a prospective study suggest that circulating tumor DNA sequencing with a large panel may efficiently identify actionable alterations in patients with advanced solid tumors.

Lifestyle choices such as diet and exercise can be useful in managing symptom burden and may even have an impact on some treatment outcomes, according to a director of Lifestyle Medicine from Massachusetts General Hospital.

OM-301, which demonstrated preclinical anti-cancer activity in multiple myeloma, receives orphan drug designation from the FDA.

Adding pembrolizumab to chemotherapy with or without bevacizumab can help patients with persistent, recurrent, or metastatic cervical cancer “live longer and better,” according to an expert from the University of Arizona College of Medicine.

In addition to the benefit seen with hormone therapy plus metastasis-directed radiation in oligometastatic prostate cancer, use of intermittent hormone therapy may result in positive disease control and longer eugonadal testosterone intervals.

Investigators highlight the importance of building partnerships between CAR T-cell centers and external hospitals to increase treatment referrals and access to clinical trials for patients with B-cell acute lymphoblastic leukemia.

The FDA sets a Prescription Drug User Fee Act date of December 16, 2023 for pembrolizumab plus chemotherapy for managing metastatic gastric or gastroesophageal junction adenocarcinoma.

Incorporating nursing-led palliative care may help to improve advanced care planning among those with advanced cancer, especially those without access to specialty palliative care.

An expert from Dana-Farber Cancer Institute highlights data that supported the FDA’s approval of sacituzumab govitecan for advanced hormone receptor–positive, HER2-negative breast cancer.

Krina Patel, MD, MSc, discusses research and initiatives that may help to mitigate disparities in patients with multiple myeloma including factors such as gender, race, and ethnicity.

Data from the interim analysis of the phase 3 FLAMES study indicate that senaparib may lengthen progression-free survival in patients with advanced ovarian cancer.

TP-1287 is under investigation as part of a phase 1 study in patients with metastatic or progressive solid tumors, including Ewing sarcoma, that are refractory or intolerant to other established therapies.

There is a clear need for further trials and drug development to mitigate poor outcomes in patients with small cell lung cancer, according to an expert from Yale School of Medicine.

CB-011, which received fast track designation from the FDA, is currently under investigation as a treatment for those with relapsed or refractory multiple myeloma in the phase 1 CaMMouflage trial.

Investigators behind a phase 1 trial investigating MT-0169 in relapsed or refractory multiple myeloma and non-Hodgkin lymphoma will pause enrollment of new patients following prior reports of cardiac adverse effects in 2 patients.

Tavokinogene telseplasmid plus pembrolizumab is reported to be well tolerated in patients with advanced, pre-treated melanoma based on data from the phase 2 KEYNOTE-695 trial.

Primary outcome data from phase 3 confirmatory studies evaluating ibrutinib in mantle cell lymphoma and marginal zone lymphoma are insufficient to support conversion to full FDA approval in these indications.

SynKIR-110, which received fast track designation from the FDA, is currently under investigation as treatment for patients with mesothelioma in the phase 1 STAR-101 trial.

Patients with advanced high-grade epithelial BRCA mutation–negative ovarian cancer appear to benefit from treatment with olaparib and durvalumab plus bevacizumab and chemotherapy.

Farshid Sadeghi, MD, elaborates on improvements in minimally invasive surgery technique and the interdisciplinary cooperation that goes into treating kidney cancer.

Collaboration in kidney cancer palliative care and integrative medicine programs underscores the current development of University Hospitals’ integrative oncology wing.